B Bielekova Selected Research

CGP 77116

10/2000

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

B Bielekova Research Topics

Disease

11	Multiple Sclerosis 04/2015 - 01/2000
3	Autoimmune Diseases (Autoimmune Disease) 10/2001 - 01/2000
1	Neoplasms (Cancer) 10/2001
1	Lyme Disease (Disease, Lyme) 05/2001
1	Relapsing-Remitting Multiple Sclerosis 01/2000
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2000

Drug/Important Bio-Agent (IBA)

3	AntigensIBA 05/2001 - 01/2000
2	Daclizumab (Zenapax)FDA Link 02/2014 - 11/2011
2	Interferon-betaIBA 09/2001 - 11/2000
2	Proteins (Proteins, Gene)FDA Link 05/2001 - 01/2000
2	Peptides (Polypeptides)IBA 10/2000 - 01/2000
2	Amino Acids FDA Link 10/2000 - 01/2000
2	Myelin Basic ProteinIBA 10/2000 - 05/2000
1	daclizumab HYPIBA 04/2015
1	InterferonsIBA 11/2011
1	Monoclonal AntibodiesIBA 11/2011
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2001
1	LigandsIBA 10/2000
1	CGP 77116IBA 10/2000
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 05/2000
1	EpitopesIBA 01/2000
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 01/2000
1	Myelin ProteinsIBA 01/2000

Therapy/Procedure

2	Therapeutics 10/2005 - 11/2000
2	Immunotherapy 10/2001 - 10/2000